Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus
NCT06913023Phase 3Not yet recruiting
- Sponsor
- University Health Network
- Start
- Sep 2026
- Primary completion
- Jun 2029
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in post-transplant diabetes mellitus (PTDM), sponsored by University Health Network. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
03
Conditions
post-transplant diabetes mellitus (PTDM)
Beyond the preview
Go deeper on NCT06913023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06913023.